Jacobio Pharmaceuticals Group Co., Ltd.
1167.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.36B
Close$
$0.04
99.2% downside
Current Fair Value
99.2% downsideOvervalued by 99.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.36 Billion |
|---|---|
| Enterprise Value | $4.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.18 |
| Beta | 0.3 |
| Outstanding Shares | 778,854,000 |
Return
| Return on Equity | 34.13% |
|---|---|
| Return on Assets | 24.75% |
| Return on Invested Capital | 25.08% |
Valuation & Multiples
| P/E Ratio | 7.29 |
|---|---|
| PEG | -0.66 |
| Price to Sales | 5.12 |
| Price to Book Ratio | 5.12 |
| Enterprise Value to Revenue | 4.65 |
| Enterprise Value to EBIT | 10.42 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$754.18 M
Average shareholder expectationNext Earnings Call
Expected Date
March 24, 2027
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$23.21 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jacobio Pharmaceuticals Group Co., Ltd.
207 employees
CEO: Yinxiang Wang Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage alloster...